/Investor DB

Debiopharm Innovation Fund — 2023 Investments

4 investments dated 2023 · listed companies and verified rows first · show all

Altisaltis.vcJun 2023

Altis provides primary research and commercial due diligence for venture investors, with a focus on AI-sector analysis to help evaluate startups and investment opportunities.

AI & Machine LearningData & InfrastructureEnterprise SoftwareFintechNew York, US

Ben Sun(Co-founder)Chris Freeberg(Founder & CEO)Jason Seu(Founding Chief Research Officer)Stanley Gu(Founding Engineer)

Co-investorsPrimary Venture PartnersBenchstrength PartnersGalapagos Capital

Altis Labsaltislabs.comin𝕏Jun 2023

Altis Labs provides a web-based platform that applies AI models to medical imaging data to generate reproducible predictions and quantifications for clinical trials.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesToronto, CA

Felix Baldauf-Lenschen(Founder & CEO)inJohn(CTO)

Co-investorsBenchstrength PartnersCreative Destruction Lab (CDL)FusionOrbiMed

Genialisgenialis.cominMar 2023 · $13M

Genialis is a precision oncology company that applies data analysis to help drug developers understand mechanisms of action, resistance, and patient stratification for cancer therapies.

AI & Machine LearningBiotechDigital HealthMedical DevicesBoston, US

Miha Štajdohar(Executive Officer, Director)inRafael Rosengarten(Chief Executive Officer and Co-founder)inLuka Ausec(Executive Officer)inHamzeh Abdul-Hadi(Director)Tjasa Krisper Kutin(Executive Officer)

BoardIta Lu(Director)in

Co-investorsAngelini VenturesTaiwania CapitalFirst Star VenturesScaleX Venturesredalpine

Iktosiktos.aiinMar 2023

Spaya is an AI-powered retrosynthesis platform that identifies synthetic routes to target compounds by converting them into commercially available starting materials.

AI & Machine LearningBiotechDeep TechMedical DevicesParis, FR

Yann(Co-founder and CEO)Quentin(Co-founder and CSO)Nicolas(Co-founder and CTO)Yann Gaston-Mathe(Founder)

Co-investorsAgoranovM VenturesOmnes Capital

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.